SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day in Stockholm on Wednesday, June 4, 2025.
SynAct is progressing with the recruitment of patients to its Phase 2b ADVANCE study in patients with newly diagnosed severe rheumatoid arthritis (RA) and is accelerating its plans to expand the use of resomelagon into other indications. Please join the CMD to hear about SynAct’s efforts and path forward.
The agenda and more detailed information will be announced closer to the event.
When: June 4, 2025, from 15:00-17:00 CEST
Location: Sergelkonferensen
Address: Mäster Samuelsgatan 42, Stockholm
Conference room: Wall Street
Registration for the event is made by mailing [email protected]